Brief Research Report ARTICLE
Genomic profiling of driver gene mutations in Chinese patients with non-small cell lung cancer
- 1Department of Pathology, Harbin Medical University Cancer Hospital, China
- 2Geneis (Beijing) Co. Ltd, China
- 3Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, China
Worldwide, especially in China, lung cancer accounts to a major cause of mortality related to cancer. Treatment decisions mainly depend on oncogenic driver mutations, which offer novel therapeutic targets for anticancer therapy. However, studies of genomic profiling of driver gene mutations in mainland China are rare. Hence, this is an extensive study of these mutations in NSCLC Chinese patients. Comparison of driver gene mutations of lung adenocarcinoma with other races showed that the mutational frequencies were similar within the different East Asian populations, while there was quite difference between East Asian and non-Asian populations. Furthermore, four promising candidates for druggable mutations of EGFR were revealed, that open up avenues to develop and design personal therapeutic approaches for patients harboring mutations. These results will help to develop personalized therapy targeting NSCLC.
Keywords: lung cancer, driver mutations, Epidemiology, EGFR, personalized medicine
Received: 08 Jan 2019;
Accepted: 23 Sep 2019.
Copyright: © 2019 Meng, Guo, Sun, Liang, Lang, Han, Lu, Zhang, An, Tian, Yuan, Xu and Geng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Dr. Dawei Yuan, Geneis (Beijing) Co. Ltd, Beijing, China, email@example.com
Dr. Shidong Xu, Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China, firstname.lastname@example.org
Dr. Jingshu Geng, Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China, email@example.com